<DOC>
	<DOCNO>NCT00002937</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness paclitaxel without PSC 833 treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Paclitaxel With Without PSC 833 Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate response rate time treatment failure paclitaxel without P-glycoprotein ( Pgp ) antagonist PSC 833 advanced breast cancer . II . For treatment arm , relate paclitaxel AUC ( area curve ) , and/or time .05 um/L , myelosuppression and/or response . III . To obtain preliminary estimate MDR group patient measure MDR1-Pgp immunostaining pretreatment biopsy 20 patient biopsy take time progression . OUTLINE : This randomize study . Patients stratify accord three criterion : 1 ) treatment within 2 year adjuvant chemotherapy vs. progression chemotherapy advance disease 2 ) measurable vs. evaluable disease 3 ) institution . Patients receive paclitaxel alone paclitaxel plus PSC 833 . In first arm , paclitaxel alone administer continuous infusion 3 hour every 3 week . In second arm , PSC 833 administer PO four time day 3 day ; paclitaxel administer continuous infusion 3 hour day 2 . Courses repeat every 3 week . PROJECTED ACCRUAL : Approximately 70 patient accrue per year study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Metastatic breast cancer within 2 year adjuvant anthracycline base chemotherapy advanced disease , failure one prior anthracycline base chemotherapeutic regimen advance breast cancer Exception : When anthracyclines contraindicate , metastatic disease within 2 year adjuvant cytotoxic regimen , failure one prior cytotoxic chemotherapeutic regimen advance breast cancer also qualify Evaluable measurable disease least one nonirradiated area No CNS metastases PATIENT CHARACTERISTICS : Age : Not specify Performance status : SWOG 02 Life expectancy : Not specify Hematopoietic : Platelet count least 100,000/mm3 Hemoglobin least 8.0 g/dL Absolute neutrophil count least 1500/mm3 Hepatic : Total serum bilirubin great 1.5 mg/dL No history chronic active hepatitis cirrhosis SGOT and/or SGPT great 2 time upper limit normal Renal : Serum creatinine great 2.0 mg/dL Other : Not HIV positive Not pregnant nursing Effective contraceptive require fertile patient No uncontrolled nausea , vomit , diarrhea , malabsorption syndrome bowel obstruction No history second malignancy exception nonmelanoma skin cancer carcinoma situ cervix No known hypersensitivity ingredient study medication cyclosporine No neurologic problem require treatment No treatment drug within 48 hour know interact cyclosporine PRIOR CONCURRENT THERAPY : At least 4 week since investigational therapy Biologic therapy : No concurrent antibiotic , e.g . clarithromycin , erythromycin , nafcillin , rifampin , itraconazole , ketoconazole , fluconazole ( great 200 mg/day allow ) Chemotherapy : No prior paclitaxel At least 6 week since nitrosoureas At least 4 week since myelosuppressive chemotherapy Endocrine therapy : At least 2 week since hormone therapy No concurrent danazol Radiotherapy : At least 3 week since radiation therapy Surgery : Must recover previous surgery Other : No concurrent calcium channel blocker , e.g . diltiazem , nicardipine , verapamil No concurrent anticonvulsant , e.g . carbamazepine , phenobarbital , phenytoin No concurrent bromocriptine</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>recurrent breast cancer</keyword>
</DOC>